PL4223750T3 - Związki bicykliczne zawierające azot, które zawierają pirymidynę, jako inhibitory kinazy 4 związanej z receptorem interleukiny 1 (irak-4) do stosowania w leczeniu chorób zapalnych lub autoimmunologicznych - Google Patents
Związki bicykliczne zawierające azot, które zawierają pirymidynę, jako inhibitory kinazy 4 związanej z receptorem interleukiny 1 (irak-4) do stosowania w leczeniu chorób zapalnych lub autoimmunologicznychInfo
- Publication number
- PL4223750T3 PL4223750T3 PL20956217.2T PL20956217T PL4223750T3 PL 4223750 T3 PL4223750 T3 PL 4223750T3 PL 20956217 T PL20956217 T PL 20956217T PL 4223750 T3 PL4223750 T3 PL 4223750T3
- Authority
- PL
- Poland
- Prior art keywords
- irak
- interleukin
- inflammatory
- inhibitors
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2020/037048 WO2022070289A1 (ja) | 2020-09-30 | 2020-09-30 | ピリミジン含有含窒素二環化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4223750T3 true PL4223750T3 (pl) | 2025-09-15 |
Family
ID=80951519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20956217.2T PL4223750T3 (pl) | 2020-09-30 | 2020-09-30 | Związki bicykliczne zawierające azot, które zawierają pirymidynę, jako inhibitory kinazy 4 związanej z receptorem interleukiny 1 (irak-4) do stosowania w leczeniu chorób zapalnych lub autoimmunologicznych |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240025893A1 (pl) |
| EP (1) | EP4223750B1 (pl) |
| JP (1) | JP7433463B2 (pl) |
| KR (1) | KR20230084145A (pl) |
| CN (1) | CN116194454B (pl) |
| AU (1) | AU2020471055B8 (pl) |
| CA (1) | CA3194164A1 (pl) |
| ES (1) | ES3036969T3 (pl) |
| MX (1) | MX2023003698A (pl) |
| PL (1) | PL4223750T3 (pl) |
| WO (1) | WO2022070289A1 (pl) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101995013B1 (ko) * | 2010-07-13 | 2019-07-02 | 에프. 호프만-라 로슈 아게 | Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체 |
| MX366318B (es) * | 2010-11-19 | 2019-07-05 | Ligand Pharm Inc | Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1. |
| EP2688872A4 (en) * | 2011-03-22 | 2014-08-27 | Merck Sharp & Dohme | AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| US8987311B2 (en) * | 2012-01-13 | 2015-03-24 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| EP3049086A4 (en) | 2013-09-27 | 2017-02-22 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2015150995A1 (en) | 2014-04-04 | 2015-10-08 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors |
| US9969749B2 (en) | 2014-09-30 | 2018-05-15 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| WO2016144846A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of irak4 activity |
| CN108473498B (zh) * | 2015-12-22 | 2021-11-02 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
| CN106946890A (zh) * | 2017-04-26 | 2017-07-14 | 中国药科大学 | 吡啶类irak4抑制剂、其制备方法及应用 |
| KR102858188B1 (ko) * | 2017-10-02 | 2025-09-11 | 주식회사 퍼스트바이오테라퓨틱스 | 벤조티아졸 화합물 및 신경퇴행성 질환을 치료하기 위한 그의 사용 방법 |
-
2020
- 2020-09-30 EP EP20956217.2A patent/EP4223750B1/en active Active
- 2020-09-30 MX MX2023003698A patent/MX2023003698A/es unknown
- 2020-09-30 CN CN202080105488.8A patent/CN116194454B/zh active Active
- 2020-09-30 KR KR1020237010766A patent/KR20230084145A/ko not_active Ceased
- 2020-09-30 ES ES20956217T patent/ES3036969T3/es active Active
- 2020-09-30 JP JP2022553287A patent/JP7433463B2/ja active Active
- 2020-09-30 AU AU2020471055A patent/AU2020471055B8/en active Active
- 2020-09-30 CA CA3194164A patent/CA3194164A1/en active Pending
- 2020-09-30 PL PL20956217.2T patent/PL4223750T3/pl unknown
- 2020-09-30 WO PCT/JP2020/037048 patent/WO2022070289A1/ja not_active Ceased
- 2020-09-30 US US18/029,289 patent/US20240025893A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2022070289A1 (pl) | 2022-04-07 |
| JP7433463B2 (ja) | 2024-02-19 |
| EP4223750A4 (en) | 2024-06-19 |
| EP4223750B1 (en) | 2025-06-25 |
| WO2022070289A1 (ja) | 2022-04-07 |
| CA3194164A1 (en) | 2022-04-07 |
| US20240025893A1 (en) | 2024-01-25 |
| AU2020471055B8 (en) | 2023-12-21 |
| MX2023003698A (es) | 2023-06-15 |
| AU2020471055A1 (en) | 2023-05-04 |
| KR20230084145A (ko) | 2023-06-12 |
| EP4223750A1 (en) | 2023-08-09 |
| AU2020471055B2 (en) | 2023-12-14 |
| CN116194454B (zh) | 2025-02-18 |
| CN116194454A (zh) | 2023-05-30 |
| ES3036969T3 (en) | 2025-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3873477A4 (en) | CYCLIN DEPENDENT KINASE 7 (CDK7) INHIBITOR | |
| AR118162A2 (es) | Procesos e intermedios para hacer un inhibidor de jak | |
| MX2025011774A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
| JOP20200209A1 (ar) | مثبطات cd73 | |
| ZA201903932B (en) | Imidazopyrazine inhibitors of bruton's tyrosine kinase | |
| MX384172B (es) | Derivados de pirazol pirimidina y sus usos. | |
| CL2008003023A1 (es) | (s)-4-amino-n-(1-(4-clorofenil)-3-hidroxipropil)-1-(7h-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida, inhibidor de la proteina quinasa b; procedimiento de preparacion; compuestos intermediarios; composicion farmacéutica que comprende dicho compuesto; y uso para el tratamiento del cancer. | |
| NZ711540A (en) | Fused heterocyclic compounds as protein kinase inhibitors | |
| MX2020008559A (es) | Compuestos heterocíclicos como inhibidores de la quinasa. | |
| EP3740206A4 (en) | INHIBITORS OF THE CYCLINE-DEPENDENT KINASE 7 (CDK7) | |
| MA51619A (fr) | Inhibiteurs de la protéine kinase dépendante de l'adn | |
| IL289038A (en) | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | |
| SG11202011513RA (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| EA201890827A1 (ru) | Конденсированные производные пиразола в качестве ингибиторов киназы | |
| MX2010005950A (es) | 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa. | |
| SI3317281T1 (sl) | Trdne oblike in formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin -2-il)imidazo(1,5-a)pirazin-1-il)-n-(piridin-2-il)benzamida | |
| ZA202205900B (en) | 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer | |
| CL2008001705A1 (es) | Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3. | |
| PL3952995T3 (pl) | Pochodne bicyklicznych heteroaryli jako inhibitory ekto- pirofosfatazy/fosfodiesterazy nukleotydowej 1 | |
| PL3972604T3 (pl) | Inhibitor kinazy tyrozynowej brutona do zastosowania w leczeniu przewlekłej pokrzywki spontanicznej | |
| IL287745A (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| PL4229056T3 (pl) | Związki triazolopirydynylu jako inhibitory kinaz | |
| MX2020007036A (es) | Combinaciones de inhibidores ripk1 e ikk para la prevención o tratamiento de enfermedades inmunitarias. | |
| PH12018502242A1 (en) | Imidazolone compounds as human neutrophil elastase inhibitors | |
| MA52629A (fr) | Agents inhibiteurs de la tyrosine kinase de bruton |